CCM
BMRN icon

Chiron Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Chiron Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+5,850
New +$320K 0.3% 81
2020
Q4 		– Sell
-1,950
Closed -$148K – 123
2020
Q3 		$148K Buy
+1,950
New +$197K 0.12% 84

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Chiron Capital Management's BMRN Position: Q2 2026 in Review

Chiron Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 5,850 shares worth $335K. The stake represents 0.3% of the portfolio and ranks #81 among its holdings. This is a return to the name: Chiron Capital Management previously reported a position in BMRN as recently as Q3 2020.

Chiron Capital Management first reported a position in BMRN in Q3 2020 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Chiron Capital Management held 5,850 shares of BioMarin Pharmaceuticals worth $335K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Chiron Capital Management position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.3% of Chiron Capital Management's portfolio in Q2 2026, its #81 holding.
  • Chiron Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Chiron Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.